SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Aethlon Medical, Inc.
(NASDAQ:AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announces the pricing of
a public offering of an aggregate of 5,454,546 units. Each unit is comprised of one share of common stock (or common stock
equivalent) and one common warrant to purchase one share of common stock. The units are being offered at a price of $1.10 per unit.
Each common warrant has an exercise price of $1.10 per share, is exercisable immediately and
will expire five years from the date of issuance. The shares of common stock (or common stock equivalent) and the accompanying
common warrants included in the units can only be purchased together in this offering but will be issued separately. This
offering is expected to close on or about October 4, 2017, subject to customary closing conditions.
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The gross proceeds of the offering are expected to be approximately $6 million, prior to
deducting placement agent fees and other estimated offering expenses.
The Company intends to use the net proceeds of this offering to continue the clinical development of its product candidates
and for working capital and other general corporate purposes.
A registration statement on Form S-1 (File No. 333-219589) relating to these securities was declared effective by the
Securities and Exchange Commission (SEC) on September 29, 2017. The offering is being made only by
means of a prospectus forming part of the effective registration statement. A preliminary prospectus relating to and describing
the terms of the offering has been filed with the SEC. Copies of the preliminary prospectus, and when available, copies of the
final prospectus relating to the offering may be obtained for free by visiting the SEC's website at www.sec.gov or from H.C. Wainwright &
Co., LLC, 430 Park Avenue, 4th Floor, New York, New York 10022, by email
at placements@hcwco.com or by telephone at
646-975-6996.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be
unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Aethlon Medical
Aethlon Medical is focused on addressing unmet needs in global health and biodefense. The Aethlon Hemopurifier® is a
first-in-class therapeutic device designed to address life-threatening viral infections. The United States Food and Drug
Administration (FDA) has designated the Hemopurifier® to an Expedited Access Pathway (EAP) related to the treatment of
life-threatening viruses that are not addressed with approved therapies.
In collaboration with leading government and non-government research institutes, Aethlon has validated the ability of the
Hemopurifier® to capture a broad-spectrum of pandemic influenza viruses, mosquito-borne viruses and deadly hemorrhagic
viruses. Based on its use to treat Ebola virus, the Hemopurifier® was named a "Top 25 Invention" and one of the "Eleven
Most Remarkable Advances in Healthcare," by TIME Magazine.
Aethlon is also investigating the potential therapeutic use of the Hemopurifier® to reduce the presence of tumor-derived
exosomes, which contribute to immune-suppression and the spread of metastasis in cancer patients. Additionally, Aethlon is
the majority owner of Exosome Sciences, Inc. (ESI), which is focused on the discovery of exosomal biomarkers to diagnose and
monitor cancer and neurological disorders, including Alzheimer's disease (AD) and Chronic Traumatic Encephalopathy (CTE).
Additional information can be found online at www.AethlonMedical.com and www.ExosomeSciences.com. You can also connect with us on Twitter, LinkedIn, Facebook and Google+.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as
"may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," or similar expressions
constitute forward-looking statements. Forward-looking statement includes statements relating to the public offering and the
satisfaction of closing conditions relating to the public offering, as well as general economic and market factors. Such
forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the
results anticipated in the forward-looking statements. Factors that may contribute to such differences include, without
limitation, the Company's ability to maintain its listing on the Nasdaq Capital Market, or any other national securities
exchange, that the Company or its subsidiary will not be able to commercialize its products, that the FDA will not approve the
initiation or continuation of the Company's clinical programs or provide market clearance of the Company's products, the
Company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the
Company's ability to manufacture its products either internally or through outside companies, the impact of government
regulations, patent protection on the Company's proprietary technology, the ability of the Company to meet the milestones
contemplated in its contract with DARPA, product liability exposure, uncertainty of market acceptance, competition, technological
change, and other risk factors. The foregoing list of risks and uncertainties is illustrative, but is not exhaustive. Additional
factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the
caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended March 31, 2017, and in the Company's
other filings with the Securities and Exchange Commission. Except as may be required by law, the Company does not intend, nor
does it undertake any duty, to update this information to reflect future events or circumstances.
Company Contact:
Jim Frakes
Chief Financial Officer
Aethlon Medical, Inc.
858-459-7800 x3300
Jfrakes@aethlonmedical.com
Investor Relations:
John Marco
CORE IR
516 222 2560
johnm@coreir.com
View original content:http://www.prnewswire.com/news-releases/aethlon-medical-announces-pricing-of-6-million-public-offering-300528909.html
SOURCE Aethlon Medical, Inc.